148 related articles for article (PubMed ID: 19843666)
1. The mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) enhances the radiation responsiveness of lung and colorectal tumor xenografts.
Shannon AM; Telfer BA; Smith PD; Babur M; Logie A; Wilkinson RW; Debray C; Stratford IJ; Williams KJ; Wedge SR
Clin Cancer Res; 2009 Nov; 15(21):6619-29. PubMed ID: 19843666
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase.
Chung EJ; Brown AP; Asano H; Mandler M; Burgan WE; Carter D; Camphausen K; Citrin D
Clin Cancer Res; 2009 May; 15(9):3050-7. PubMed ID: 19366835
[TBL] [Abstract][Full Text] [Related]
3. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models.
Davies BR; Logie A; McKay JS; Martin P; Steele S; Jenkins R; Cockerill M; Cartlidge S; Smith PD
Mol Cancer Ther; 2007 Aug; 6(8):2209-19. PubMed ID: 17699718
[TBL] [Abstract][Full Text] [Related]
4. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor.
Yeh TC; Marsh V; Bernat BA; Ballard J; Colwell H; Evans RJ; Parry J; Smith D; Brandhuber BJ; Gross S; Marlow A; Hurley B; Lyssikatos J; Lee PA; Winkler JD; Koch K; Wallace E
Clin Cancer Res; 2007 Mar; 13(5):1576-83. PubMed ID: 17332304
[TBL] [Abstract][Full Text] [Related]
5. Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines.
Balmanno K; Chell SD; Gillings AS; Hayat S; Cook SJ
Int J Cancer; 2009 Nov; 125(10):2332-41. PubMed ID: 19637312
[TBL] [Abstract][Full Text] [Related]
6. Targeting inhibition of extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) suppresses growth and angiogenesis of gastric cancer.
Gao JH; Wang CH; Tong H; Wen SL; Huang ZY; Tang CW
Sci Rep; 2015 Nov; 5():16382. PubMed ID: 26567773
[TBL] [Abstract][Full Text] [Related]
7. The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel.
Haass NK; Sproesser K; Nguyen TK; Contractor R; Medina CA; Nathanson KL; Herlyn M; Smalley KS
Clin Cancer Res; 2008 Jan; 14(1):230-9. PubMed ID: 18172275
[TBL] [Abstract][Full Text] [Related]
8. Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma.
Huynh H; Soo KC; Chow PK; Tran E
Mol Cancer Ther; 2007 Jan; 6(1):138-46. PubMed ID: 17237274
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.
Qu Y; Wu X; Yin Y; Yang Y; Ma D; Li H
J Exp Clin Cancer Res; 2014 Jun; 33(1):52. PubMed ID: 24939055
[TBL] [Abstract][Full Text] [Related]
10. MEK1/2 inhibition enhances the radiosensitivity of cancer cells by downregulating survival and growth signals mediated by EGFR ligands.
Chung EJ; Urick ME; Kurshan N; Shield W; Asano H; Smith PD; Scroggins BS; Burkeen J; Citrin DE
Int J Oncol; 2013 Jun; 42(6):2028-36. PubMed ID: 23588995
[TBL] [Abstract][Full Text] [Related]
11. The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models.
Holt SV; LogiƩ A; Odedra R; Heier A; Heaton SP; Alferez D; Davies BR; Wilkinson RW; Smith PD
Br J Cancer; 2012 Feb; 106(5):858-66. PubMed ID: 22343622
[TBL] [Abstract][Full Text] [Related]
12. Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.
Tai YT; Fulciniti M; Hideshima T; Song W; Leiba M; Li XF; Rumizen M; Burger P; Morrison A; Podar K; Chauhan D; Tassone P; Richardson P; Munshi NC; Ghobrial IM; Anderson KC
Blood; 2007 Sep; 110(5):1656-63. PubMed ID: 17510321
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.
Migliardi G; Sassi F; Torti D; Galimi F; Zanella ER; Buscarino M; Ribero D; Muratore A; Massucco P; Pisacane A; Risio M; Capussotti L; Marsoni S; Di Nicolantonio F; Bardelli A; Comoglio PM; Trusolino L; Bertotti A
Clin Cancer Res; 2012 May; 18(9):2515-25. PubMed ID: 22392911
[TBL] [Abstract][Full Text] [Related]
14. Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefit.
Williams KJ; Telfer BA; Shannon AM; Babur M; Stratford IJ; Wedge SR
Mol Cancer Ther; 2007 Feb; 6(2):599-606. PubMed ID: 17308057
[TBL] [Abstract][Full Text] [Related]
15. Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI.
Beloueche-Babari M; Jamin Y; Arunan V; Walker-Samuel S; Revill M; Smith PD; Halliday J; Waterton JC; Barjat H; Workman P; Leach MO; Robinson SP
Br J Cancer; 2013 Sep; 109(6):1562-9. PubMed ID: 23942066
[TBL] [Abstract][Full Text] [Related]
16. Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer.
Tentler JJ; Nallapareddy S; Tan AC; Spreafico A; Pitts TM; Morelli MP; Selby HM; Kachaeva MI; Flanigan SA; Kulikowski GN; Leong S; Arcaroli JJ; Messersmith WA; Eckhardt SG
Mol Cancer Ther; 2010 Dec; 9(12):3351-62. PubMed ID: 20923857
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice.
Denton CL; Gustafson DL
Cancer Chemother Pharmacol; 2011 Feb; 67(2):349-60. PubMed ID: 20407895
[TBL] [Abstract][Full Text] [Related]
18. MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model.
Bartholomeusz C; Oishi T; Saso H; Akar U; Liu P; Kondo K; Kazansky A; Krishnamurthy S; Lee J; Esteva FJ; Kigawa J; Ueno NT
Mol Cancer Ther; 2012 Feb; 11(2):360-9. PubMed ID: 22144664
[TBL] [Abstract][Full Text] [Related]
19. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins.
Friday BB; Yu C; Dy GK; Smith PD; Wang L; Thibodeau SN; Adjei AA
Cancer Res; 2008 Aug; 68(15):6145-53. PubMed ID: 18676837
[TBL] [Abstract][Full Text] [Related]
20. Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models.
Flanigan SA; Pitts TM; Newton TP; Kulikowski GN; Tan AC; McManus MC; Spreafico A; Kachaeva MI; Selby HM; Tentler JJ; Eckhardt SG; Leong S
Clin Cancer Res; 2013 Nov; 19(22):6219-29. PubMed ID: 24045180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]